These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 26010016

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR, Becker RC, Breithardt G, Hacke W, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Piccini JP, Mahaffey KW, Fox KA, ROCKET AF Steering Committee and Investigators.
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [Abstract] [Full Text] [Related]

  • 3. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ, Amerena JV.
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI, Turpie AGG, Bunz TJ, Eriksson D, Sood NA, Baker WL.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):64-69. PubMed ID: 30020424
    [Abstract] [Full Text] [Related]

  • 5. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
    Cieri NE, Kusmierski K, Lackie C, Van Opdorp A, Hassan AK.
    Pharmacotherapy; 2017 Feb 01; 37(2):170-176. PubMed ID: 28028830
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M, Minematsu K, Toyoda K, Yamagami H, Yoshimura S, Nagao T, Mori E, Hirano T, Hamasaki T, Yamaguchi T.
    J Stroke Cerebrovasc Dis; 2016 Jun 01; 25(6):1342-8. PubMed ID: 26987488
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR.
    Am J Cardiol; 2017 Nov 15; 120(10):1837-1840. PubMed ID: 28886856
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation.
    Lee HF, Chan YH, Tu HT, Kuo CT, Yeh YH, Chang SH, Wu LS, See LC.
    Int J Cardiol; 2018 Jun 15; 261():78-83. PubMed ID: 29559181
    [Abstract] [Full Text] [Related]

  • 12. Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study.
    Uchiyama S, Atarashi H, Inoue H, Kitazono T, Yamashita T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Shimokawa H.
    Heart Vessels; 2019 Jan 15; 34(1):141-150. PubMed ID: 29980835
    [Abstract] [Full Text] [Related]

  • 13. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
    Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR.
    Circulation; 2016 Jan 26; 133(4):352-60. PubMed ID: 26673560
    [Abstract] [Full Text] [Related]

  • 14. A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia.
    Alosaimi HM, Alqahtani S, Balkhi B, Alqahtani M, Alzamil F, Alhossan A, Alqahtany FS, Alharbi AA, Alqahtani NA, Albackr H, Elgohary G, Algahtani FH.
    PeerJ; 2022 Jan 26; 10():e13974. PubMed ID: 36105646
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Murakawa Y, Iwashiro S, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.
    J Stroke Cerebrovasc Dis; 2020 Apr 26; 29(4):104584. PubMed ID: 31983518
    [Abstract] [Full Text] [Related]

  • 20. Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
    Yagi N, Suzuki S, Arita T, Otsuka T, Semba H, Kano H, Matsuno S, Kato Y, Uejima T, Oikawa Y, Yajima J, Matsuhama M, Yamashita T.
    Heart Vessels; 2020 Jan 26; 35(1):110-117. PubMed ID: 31222552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.